Medyssey receives U.S. FDA 510(k) clearance for NeckTune 3D SA Cervical Cage spinal implant

South Korean medical device manufacturer Medyssey (KOSDAQ: 200580) announced on June 16, 2026, that it has received U.S. FDA 510(k) clearance for its NeckTune 3D SA Cervical Cage, a 3D-printed standalone spinal implant. The device, cleared on June 15, 2026, is designed for anterior cervical interbody fusion (ACIF) and integrates a porous lattice structure produced via additive manufacturing to promote osseointegration. Unlike conventional implants that require a separate anterior cervical plate, the NeckTune 3D SA uses an integrated screw fixation system, eliminating the need for an additional plate and reducing surgical steps and anterior soft-tissue dissection. Medyssey expects initial U.S. revenue to begin in the second half of 2026, though the company has not disclosed specific revenue projections.

This clearance adds Medyssey to a growing cohort of Asian AM-enabled orthopedic implant makers targeting the U.S. spinal market, a segment where additive manufacturing has become the default production method for porous titanium interbody cages. The clinical value proposition - reducing operative time and minimizing dysphagia risk by eliminating the anterior plate - directly addresses long-standing surgeon preferences in ACIF procedures. Medyssey’s entry intensifies competition against established players such as NuVasive, Stryker, and Zimmer Biomet, all of whom have commercialized 3D-printed titanium cages with similar porous architectures. For Medyssey, a company listed on KOSDAQ since 2003, this FDA clearance represents a critical gateway to the world’s largest spinal implant market, where reimbursement and surgeon adoption are tightly linked to regulatory approvals and clinical evidence.

From a practical standpoint, Medyssey now faces the execution challenge of building U.S. distribution, surgeon education, and hospital value-analysis committee approvals - steps that typically take 12 to 24 months before meaningful revenue materializes. The company’s ability to differentiate its NeckTune 3D SA on clinical outcomes or cost efficiency, rather than just regulatory equivalence, will determine whether this clearance translates into sustainable market share rather than a one-time announcement.